Diana Shipping Inc. Announces the Date for the 2025 First Quarter Financial Results, Conference Call and Webcast
ATHENS, Greece, May 19, 2025 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX), (the 'Company'), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that its financial results for the first quarter ended March 31, 2025 are scheduled to be released before the opening of the U.S. financial markets on Thursday, May 29, 2025.
The Company's management will conduct a conference call and simultaneous Internet webcast to review these results at 9:00 A.M. (Eastern Time) on Thursday, May 29, 2025.
Investors may access the webcast by visiting the Company's website at www.dianashippinginc.com, and clicking on the webcast link. An accompanying investor presentation also will be available via the webcast link and on the Company's website. The conference call also may be accessed by telephone by dialing 1-877-407-8291 (for U.S.-based callers) or 1-201-689-8345 (for international callers), and asking the operator for the Diana Shipping Inc. conference call.
A replay of the webcast will be available soon after the completion of the call and will be accessible for 30 days on www.dianashippinginc.com. A telephone replay also will be available for 30 days by dialing 1-877-660-6853 (for U.S.-based callers) or 1-201-612-7415 (for international callers), and providing the Replay ID number 13753904.
About the Company
Diana Shipping Inc. is a global provider of shipping transportation services through its ownership and bareboat charter-in of dry bulk vessels. The Company's vessels are employed primarily on short to medium-term time charters and transport a range of dry bulk cargoes, including such commodities as iron ore, coal, grain and other materials along worldwide shipping routes.
Corporate Contact:
Ioannis Zafirakis
Director, Co-Chief Financial Officer,
Chief Strategy Officer,
Treasurer and Secretary
Telephone: + 30-210-9470-100
Email: [email protected]
Website: www.dianashippinginc.com
X: @Dianaship
Investor Relations/Media Contact:
Nicolas Bornozis / Daniela Guerrero
Capital Link, Inc.
230 Park Avenue, Suite 1540
New York, N.Y. 10169
Tel.: (212) 661-7566
Email: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results
FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) ('Enzo' or the 'Company') today announced financial results for the fiscal third quarter ended April 30, 2025. Financial Highlights The Company's third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, and tariffs uncertainty, as well as timing of large orders fulfillment. The Company launched approximately 100 new products during the third-quarter of fiscal year 2025, and we are focusing on driving new revenues for those products. The Company's third-quarter gross margin percentage was 39% (41% excluding a one-time inventory provision) and 47% in the 2025 and 2024 periods, respectively. The decline in the 2025 period gross profit was driven by the reduction in revenues, which did not fully cover overhead burden and other fixed manufacturing costs. Despite changes in revenue, the operating loss results for the nine months of FY25 for the Company's continuing operations decreased by $1.1 million compared to the same period in the prior year. This was achieved through cost containment initiatives and timing of litigation matters. Net loss per basic and fully diluted share was ($0.05) and ($0.06) for the three months ended April 30, 2025 and 2024, respectively. Enzo ended the third quarter with aggregate cash and cash equivalents of $36.7 million and working capital of $31.3 million. As noted below, $6.7 million of the remaining class-wide settlement will be paid in July 2025. The Board of Directors and management continue to be focused on conserving cash. Recent Events The Company and plaintiffs have reached a class-wide settlement agreement pertaining to the April 2023 cyber incident, which the Court granted approval of at the final fairness hearing on June 10, 2025. Approximately $0.8M of the settlement was paid in March 2025 and the remaining balance of $6.7 million must be remitted by July 10, 2025. On April 22, 2025 the Company announced that its Board of Directors (the 'Board') had commenced a review of strategic alternatives after receiving multiple inquiries regarding a potential transaction with the Company. In connection with this process, the Board has formed a special committee of independent directors (the 'Strategic Committee') authorized to evaluate a broad range of opportunities to maximize value for shareholders, including a potential strategic transaction, business combination, full sale of the Company or return of excess capital to shareholders. The Strategic Committee has engaged BroadOak Capital Partners as financial advisor to assist in evaluating any inbound expressions of interest and other potential transactions. The Company does not intend to disclose further developments on this strategic review process unless and until a transaction is approved and entered into, or the process is discontinued. On March 28, 2025, we notified the NYSE of our decision to voluntarily delist our common stock from NYSE. In connection with the delisting, the last day of trading of the Company's common stock on NYSE was April 17, 2025. The Company's common stock began trading on OTCQX on April 21, 2025 under the symbol 'ENZB.' About Enzo Biochem Enzo Biochem, Inc. has operated as a life sciences company for over 45 years. The primary business of Enzo today is conducted through its Life Sciences division, Enzo Life Sciences, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The Company's proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The Company monetizes its technology primarily via sales through our global distribution network and licensing. For more information, please visit or follow Enzo Biochem on X and LinkedIn. Forward-Looking Statements Except for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues and expenses, which are dependent on a number of factors outside of the control of the Company, including, inter alia, the markets for the Company's products, cost of goods sold, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company's Form 10-K for the fiscal year ended July 31, 2024. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release. Enzo Biochem ContactsFor Enzo Biochem:Patricia Eckert, Chief Financial OfficerEnzo Biochem631-755-5500peckert@ Use of Non-GAAP Financial Measures by Enzo The non-GAAP financial measures contained in this press release (including, without limitation, Adjusted net loss, EBITDA, and Adjusted EBITDA) are not GAAP measures of the Company's financial performance or liquidity and should not be considered as alternatives to net income (loss) as a measure of financial performance or cash flows from operations as measures of liquidity, or any other performance measure derived in accordance with GAAP. A reconciliation of such non-GAAP measures is included in the presentation of the Company's financial results for the quarter ended April 30, 2025 contained herein and is also available in the investor relations section of the Company's website ( The Company believes the presentation of these non-GAAP measures provides useful additional information to investors because they provide information consistent with that on which management evaluates the financial performance of the Company. The Company manages its business based on its operating cash flows. It refers to EBITDA as its primary indicator of performance and refers to Adjusted EBITDA to further exclude items of a non-recurring nature. It is reasonable to expect that one or more excluded items will occur in future periods, though the amounts recognized can vary significantly from period to period. You are encouraged to evaluate each adjustment used to determine a non-GAAP financial measure and the reasons management considers it appropriate for supplemental analysis. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. We refer you to the tables attached to this press release, which includes reconciliation tables of GAAP net loss to Adjusted net loss and GAAP net loss to EBITDA and Adjusted EBITDA. ENZO BIOCHEM, INC. (in thousands) 04/30/2025(unaudited) 7/31/2024(unaudited) Cash and cash equivalents $ 36,693 $ 52,371 Working capital 31,267 45,237 Stockholders' equity 43,398 56,112 Total assets 63,516 85,764 The following table presents a reconciliation of reported net loss and basic and diluted net loss per share to Adjusted net loss and Adjusted basic and diluted net loss per share for the three months ended April 30, 2025. ENZO BIOCHEM, INC. Non-GAAP Reconciliation Table (Unaudited, in thousands, except per share data) Three months ended April 30, 2025 Reported GAAP net loss $ (2,790 ) Adjusted for: Inventory provision 163 Discrete legal matters 88 Net loss from discontinued operations 416 Discrete separation matters 17 Adjusted net loss $ (2,106 ) Weighted Shares Outstanding: Basic and diluted 52,403 Basic and diluted earnings per share: Basic and diluted net loss per share GAAP ($0.05 ) Adjusted basic and diluted net loss per share non-GAAP ($0.04 )The following table presents a reconciliation of reported GAAP net loss for the three months ended April 30, 2025 to EBITDA and Adjusted EBITDA: ENZO BIOCHEM, INC. EBITDA & Adjusted EBITDA Reconciliation Table (Unaudited, in thousands) Three months ended April 30, 2025 GAAP net loss $ (2,790 ) Plus (minus): Depreciation and amortization 318 Interest (income), net (384 ) EBITDA (2,856 ) Adjusted for: Inventory provision 163 Discrete legal matters 88 Discrete separation expenses 17 Net loss from discontinued operations 416 Foreign exchange gain (508 ) Adjusted EBITDA $ (2,680 )Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Alpari Report Gold above $3K: the appeal of safe haven assets in volatile times after 'Liberation Day'
LONDON, June 16, 2025 /PRNewswire/ -- In March, the spot price of gold rose above $3K where it has stayed, currently sitting above $3.4K. Apart from briefly exceeding this price a few days on 14 March and dropping again, this is the first time the asset has hit this record price. A key reason for the high price of gold is the current economic and geopolitical instability. The broker Alpari has put together a report on gold and other safe-haven assets, and why investors turn to them during periods of instability. One reason for gold's reliability as a safe haven asset is its scarcity, with over 90% of the world's gold already mined according to the World Gold Council. While it is only as recently as March that gold reached the landmark price of $3,000, it had already been reaching high prices in 2024. Central banks increasing their stocks of the precious metal was one key factor, with central banks around the world purchasing over 1,000 tonnes of gold last year. Uncertainty around what the effects of President Trump's tariffs and other policies will be has caused volatility, sending U.S. investors in particular in search of safe havens. From December 2024 to 17 February, almost 20 million ounces of gold had been imported into the country, according to the World Gold Council. Alpari's guide also includes an overview of how gold is priced and how it can be traded against different currencies. The worldwide benchmark is XAUUSD, or the price of 1 troy ounce gold quoted in U.S. dollars, but 'gold crosses' against currencies can also give traders the opportunity to make a profit based on differing gold prices around the world. In 2024, gold vs the U.S. dollar or XAUUSD climbed 27%. In contrast, due to the economic situation in Japan, with labour shortages and low interest rates, gold vs the yen or XAUJPY climbed by a much higher 42%. Alexey Efimov, Market Analyst at Alpari, comments: "Trade war fears and central bank purchases should ensure that bullion's supportive drivers remain intact. The evident risks on the global landscape are playing to gold's strengths and amplifying its time-tested virtues, be it as a safe haven or an inflation hedge. About Alpari: Alpari is a long-established leader in online financial trading. They pioneered online forex trading for retail clients 25 years ago, and remain focused on enabling individuals to access the potential of global financial markets Alpari clients are individuals with an appetite to generate financial returns through self-directed trading. They are comfortable taking risks in order to generate returns and are willing to invest time to build the skills needed to succeed Alpari's promise to these clients is to enable them to "access global trading opportunities securely". They believe that individuals anywhere in the world should be able to access opportunities in financial markets - where local political environments do not support domestic regulation, they provide solutions for individuals to access our services offshore, but offering the same service standards and client protections as a regulated business. ContactHana MontgomeryShout Bravohello@ Logo - View original content to download multimedia: SOURCE Alpari Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
31 minutes ago
- Business Wire
FrontView REIT Announces Appointment of Sean Fukumura as Interim CFO
DALLAS--(BUSINESS WIRE)--FrontView REIT ('FrontView' or the 'Company') (NYSE: FVR) today announced the appointment of Sean Fukumura as Interim Chief Financial Officer of the Company, effective immediately. Mr. Fukumura will continue to serve as the Company's Chief Accounting Officer. This appointment follows the Board's decision to terminate Randall Starr for cause, effective immediately. An Audit Committee investigation, assisted by outside counsel, determined that cause existed pursuant to the terms of his employment agreement. Mr. Starr's termination is unrelated to the Company's business operations, financial results or previously filed financial statements. In accordance with Mr. Starr's employment contract, he is no longer a member of the Board nor an officer of the Company or any of its affiliates. Stephen Preston, Chairman and CEO of the Company stated 'Although this is an unfortunate situation, we have begun a search for a permanent CFO and expect to have a seasoned candidate on board in relatively short order.' About FrontView REIT, Inc. FrontView is an internally-managed net-lease REIT that acquires, owns and manages primarily properties with frontage that are net leased to a diversified group of tenants. FrontView is differentiated by an investment approach focused on properties that are in prominent locations with direct frontage on high-traffic roads that are highly visible to consumers. FrontView's tenants include service- oriented businesses, such as restaurants, cellular stores, financial institutions, automotive stores and dealers, medical and dental providers, pharmacies, convenience and gas stores, car washes, home improvement stores, grocery stores, professional services, fitness operators as well as general retail tenants.
